AstraZeneca PLC (AZN) vs Gilead Sciences, Inc. (GILD)
- AstraZeneca PLC AZN 165.41 −0.76%
- Gilead Sciences, Inc. GILD 156.19 −0.75%
AstraZeneca PLC and Gilead Sciences, Inc. are both Drug Manufacturers General companies. AstraZeneca PLC is the larger, with a market value of $258.5B against $195.1B — 1.3× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; AstraZeneca PLC trades at 24.5×. AstraZeneca PLC grew revenue faster over the last twelve months: 8.61% against 5.52%. AstraZeneca PLC has the higher net margin (17.0% vs −10.6%) and the higher return on invested capital (11.7% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (2.08% vs 1.94%). Across the 22 metrics below, AstraZeneca PLC leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | AZN | GILD | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.88% | 79.59% | 72.77% |
| Operating margin | 22.77% | (8.20%) | 18.77% |
| Net margin | 17.02% | (10.64%) | 8.27% |
| Free cash flow margin | 10.21% | 42.50% | 17.18% |
| Return on equity | 21.95% | (20.68%) | 5.87% |
| Return on assets | 9.15% | (6.17%) | 2.57% |
| Return on invested capital | 11.67% | (4.48%) | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack